New Zealand’s Pharmaceutical Management Agency, or PHARMAC, has given a reimbursement approval for Bristol-Myers Squibb’s ($BMY) Opdivo (nivolumab) to treat melanoma, while still in a back-and-forth with Merck ($MRK) on Keytruda (pembrolizumab) for the same indication.
2022
Melanoma: A Completely New Way to Attack And Kill The Most Severe Form Of Skin Cancer
For the first time, Sanford Burnham Prebys researchers under the direction of Ze’ev Ronai, Ph.D., have demonstrated that blocking a crucial metabolic enzyme specifically kills melanoma cells and slows tumor growth.
Treatment for a Rare Form of Eye Cancer Has Shifted From Removing the Eye to Preserving Vision and Extending Lives, Says Expert
An expert provides insight on how primary uveal melanoma is often treated and sheds some light on an unmet need in treating the eye cancer.
Enrollment Begins in Phase 2 Trial of Rintatolimod in PD-1/PD-L1 Resistant Melanoma
Enrollment has begun for a phase 2 study of a polarized dendritic cell vaccine plus interferon alpha-2b, rintatolimod, and celecoxib in melanoma with PD1/PD-L1-resistance.